The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1141
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Stakeholders
- Companies sponsors
- Bristol-Myers Squibb (nivolumab)
- Others
- Department of Health
- NHS England
- Welsh Government
- Patient carer groups
- British Liver Trust
- Professional groups
- Association of Cancer Physicians
- British Association of the Study of the Liver
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Associated public health groups
- None
- Comparator companies
- None
- Evidence review group
- Warwick Evidence
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Welsh Health Specialised Services committee
- Relevant research groups
- Foundation for Liver Research
- Institute of Cancer Research
- National Cancer Research Institute
Timeline
Key events during the development of the guidance:
For further information on our processes and methods, please see our CHTE processes and methods manual